{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:07:30Z","timestamp":1787731650223,"version":"build-2784847793"},"reference-count":46,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["P01AI077774"],"award-info":[{"award-number":["P01AI077774"]}]},{"name":"NIH","award":["1R01AI132695"],"award-info":[{"award-number":["1R01AI132695"]}]},{"name":"Creutzfeldt-Jakob Disease Foundation","award":["P01AI077774"],"award-info":[{"award-number":["P01AI077774"]}]},{"name":"Creutzfeldt-Jakob Disease Foundation","award":["1R01AI132695"],"award-info":[{"award-number":["1R01AI132695"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Prion diseases are 100% fatal infectious neurodegenerative diseases affecting the brains of humans and other mammals. The disease is caused by the formation and replication of prions, composed exclusively of the misfolded prion protein (PrPSc). We invented and developed the protein misfolding cyclic amplification (PMCA) technology for in vitro prion replication, which allow us to replicate the infectious agent and it is commonly used for ultra-sensitive prion detection in biological fluids, tissues and environmental samples. In this article, we studied whether PMCA can be used to screen for chemical compounds that block prion replication. A small set of compounds previously shown to have anti-prion activity in various systems, mostly using cells infected with murine prions, was evaluated for their ability to prevent the replication of prions. Studies were conducted simultaneously with prions derived from 4 species, including human, cattle, cervid and mouse. Our results show that only one of these compounds (methylene blue) was able to completely inhibit prion replication in all species. Estimation of the IC50 for methylene blue inhibition of human prions causing variant Creutzfeldt-Jakob disease (vCJD) was 7.7 \u03bcM. Finally, we showed that PMCA can be used for structure-activity relationship studies of anti-prion compounds. Interestingly, some of the less efficient prion inhibitors altered the replication of prions in some species and not others, suggesting that PMCA is useful for studying the differential selectivity of potential drugs.<\/jats:p>","DOI":"10.3390\/biom14091113","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T02:25:49Z","timestamp":1725416749000},"page":"1113","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Screening of Anti-Prion Compounds Using the Protein Misfolding Cyclic Amplification Technology"],"prefix":"10.3390","volume":"14","author":[{"given":"Sandra","family":"Pritzkow","sequence":"first","affiliation":[{"name":"Department of Neurology, Mitchell Center for Alzheimer\u2019s Disease and Related Brain Disorders, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Schauer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mitchell Center for Alzheimer\u2019s Disease and Related Brain Disorders, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6665-1488","authenticated-orcid":false,"given":"Ananya","family":"Tupaki-Sreepurna","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mitchell Center for Alzheimer\u2019s Disease and Related Brain Disorders, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-5770","authenticated-orcid":false,"given":"Rodrigo","family":"Morales","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mitchell Center for Alzheimer\u2019s Disease and Related Brain Disorders, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX 77030, USA"},{"name":"Centro Integrativo de Biologia y Quimica Aplicada (CIBQA), Universidad Bernardo O\u2019Higgins, Santiago 8370993, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Soto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mitchell Center for Alzheimer\u2019s Disease and Related Brain Disorders, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Pritzkow, S., Gorski, D., Ramirez, F., and Soto, C. (2021). Prion Dissemination through the Environment and Medical Practices: Facts and Risks for Human Health. Clin. Microbiol. Rev., 34.","DOI":"10.1128\/CMR.00059-19"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1750-3639.1998.tb00171.x","article-title":"The prion diseases","volume":"8","author":"Prusiner","year":"1998","journal-title":"Brain Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.cell.2012.05.007","article-title":"Transmissible Proteins: Expanding the Prion Heresy","volume":"149","author":"Soto","year":"2012","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1016\/j.molcel.2021.08.011","article-title":"High-resolution structure and strain comparison of infectious mammalian prions","volume":"81","author":"Kraus","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-1-4939-7244-9_16","article-title":"Insights into Mechanisms of Transmission and Pathogenesis from Transgenic Mouse Models of Prion Diseases","volume":"1658","author":"Moreno","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/B978-0-444-64012-3.00004-6","article-title":"Therapies for prion diseases","volume":"165","author":"Zafar","year":"2019","journal-title":"Handb. Clin. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/13543776.2021.1945033","article-title":"Tackling prion diseases:A review of the patent landscape","volume":"31","author":"Zattoni","year":"2021","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/35081095","article-title":"Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding","volume":"411","author":"Saborio","year":"2001","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/nprot.2012.067","article-title":"Protein misfolding cyclic amplification of infectious prions","volume":"7","author":"Morales","year":"2012","journal-title":"Nat. Protoc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00441-022-03727-5","article-title":"PMCA for ultrasensitive detection of prions and to study disease biology","volume":"392","author":"Wang","year":"2023","journal-title":"Cell Tissue Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/89895","article-title":"Protein-based PCR for prion diseases?","volume":"7","author":"Telling","year":"2001","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cell.2005.02.011","article-title":"In vitro generation of infectious scrapie prions","volume":"121","author":"Castilla","year":"2005","journal-title":"Cell"},{"key":"ref_13","first-page":"370ra183","article-title":"Detection of prions in blood from patients with variant Creutzfeldt-Jakob disease","volume":"8","author":"Pritzkow","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/nm1286","article-title":"Detection of prions in blood","volume":"11","author":"Castilla","year":"2005","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1038\/emboj.2008.181","article-title":"Cell-free propagation of prion strains","volume":"27","author":"Castilla","year":"2008","journal-title":"EMBO J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.cell.2008.07.030","article-title":"Crossing the species barrier by PrP (Sc) replication in vitro generates unique infectious prions","volume":"134","author":"Castilla","year":"2008","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Barria, M.A., Mukherjee, A., Gonzalez-Romero, D., Morales, R., and Soto, C. (2009). De novo generation of infectious prions in vitro produces a new disease phenotype. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000421"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2018.10.001","article-title":"Cell-free prion protein conversion assays in screening for anti-prion drug candidates","volume":"44","author":"Caughey","year":"2019","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00441-022-03676-z","article-title":"Prion strains viewed through the lens of cryo-EM","volume":"392","author":"Manka","year":"2023","journal-title":"Cell Tissue Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Terry, C., Harniman, R.L., Sells, J., Wenborn, A., Joiner, S., Saibil, H.R., Miles, M.J., Collinge, J., and Wadsworth, J.D.F. (2019). Structural features distinguishing infectious ex vivo mammalian prions from non-infectious fibrillar assemblies generated in vitro. Sci. Rep., 9.","DOI":"10.1038\/s41598-018-36700-w"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Schmidt, C., Fizet, J., Properzi, F., Batchelor, M., Sandberg, M.K., Edgeworth, J.A., Afran, L., Ho, S., Badhan, A., and Klier, S. (2015). A systematic investigation of production of synthetic prions from recombinant prion protein. Open Biol., 5.","DOI":"10.1098\/rsob.150165"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8462","DOI":"10.1128\/JVI.77.15.8462-8469.2003","article-title":"Evaluation of quinacrine treatment for prion diseases","volume":"77","author":"Barret","year":"2003","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ghaemmaghami, S., Ahn, M., Lessard, P., Giles, K., Legname, G., DeArmond, S.J., and Prusiner, S.B. (2009). Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000673"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"E4160","DOI":"10.1073\/pnas.1317164110","article-title":"Drug resistance confounding prion therapeutics","volume":"110","author":"Berry","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1471-4159.1992.tb09437.x","article-title":"Potent inhibition of scrapie-associated PrP accumulation by congo red","volume":"59","author":"Caughey","year":"1992","journal-title":"J. Neurochem."},{"key":"ref_26","first-page":"406","article-title":"Evaluation of anti-prion activity of congo red and its derivatives in experimentally infected hamsters","volume":"54","author":"Poli","year":"2004","journal-title":"Arzneimittelforschung"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1099\/0022-1317-81-4-1155","article-title":"Screening Congo Red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells","volume":"81","author":"Rudyk","year":"2000","journal-title":"J. Gen. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1046\/j.1471-4159.1998.71062534.x","article-title":"Structural aspects of Congo red as an inhibitor of protease-resistant prion protein formation","volume":"71","author":"Demaimay","year":"1998","journal-title":"J. Neurochem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1074\/jbc.273.6.3484","article-title":"The anti-prion activity of Congo red","volume":"273","author":"Caspi","year":"1998","journal-title":"Putative Mech. J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/01.LAB.0000074919.08232.A2","article-title":"Differential inhibition of prion propagation by enantiomers of quinacrine","volume":"83","author":"Ryou","year":"2003","journal-title":"Lab. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9836","DOI":"10.1073\/pnas.161274798","article-title":"Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease","volume":"98","author":"Korth","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ana.10336","article-title":"Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model","volume":"52","author":"Collins","year":"2002","journal-title":"Ann. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1212\/WNL.0b013e3182a9f3b4","article-title":"Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease","volume":"81","author":"Geschwind","year":"2013","journal-title":"Neurology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1474-4422(09)70049-3","article-title":"Safety and efficacy of quinacrine in human prion disease (PRION-1 study):A patient-preference trial","volume":"8","author":"Collinge","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1128\/JVI.77.9.5499-5502.2003","article-title":"Inhibition of protease-resistant prion protein accumulation in vitro by curcumin","volume":"77","author":"Caughey","year":"2003","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"10288","DOI":"10.1128\/JVI.77.19.10288-10294.2003","article-title":"New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products","volume":"77","author":"Kocisko","year":"2003","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Hyeon, J.W., Kim, S.Y., Lee, S.M., Lee, J., An, S.S., Lee, M.K., and Lee, Y.S. (2017). Anti-Prion Screening for Acridine, Dextran, and Tannic Acid using Real Time-Quaking Induced Conversion: A Comparison with PrPSc-Infected Cell Screening. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0170266"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bbadis.2012.09.005","article-title":"Binding of methylene blue to a surface cleft inhibits the oligomerization and fibrillization of prion protein","volume":"1832","author":"Cavaliere","year":"2013","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.phrs.2016.09.010","article-title":"Novel celecoxib analogues inhibit glial production of prostaglandin E2, nitric oxide, and oxygen radicals reverting the neuroinflammatory responses induced by misfolded prion protein fragment 90-231 or lipopolysaccharide","volume":"113","author":"Villa","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_40","first-page":"742","article-title":"Inhibition of Tau Protein Aggregation by Rhodanine-based Compounds Solubilized Via Specific Formulation Additives to Improve Bioavailability and Cell Viability","volume":"14","author":"Pickhardt","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Stincardini, C., Massignan, T., Biggi, S., Elezgarai, S.R., Sangiovanni, V., Vanni, I., Pancher, M., Adami, V., Moreno, J., and Stravalaci, M. (2017). An antipsychotic drug exerts anti-prion effects by altering the localization of the cellular prion protein. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0182589"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"De, L.A., Colombo, L., Diomede, L., Capobianco, R., Mangieri, M., Miccolo, C., Limido, L., Forloni, G., Tagliavini, F., and Salmona, M. (2008). The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0001888"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1474-4422(22)00083-7","article-title":"Investigating new treatments for Creutzfeldt-Jakob disease","volume":"21","author":"Zerr","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_44","first-page":"176","article-title":"Therapies for human prion diseases","volume":"2","author":"Panegyres","year":"2013","journal-title":"Am. J. Neurodegener. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1099\/vir.0.009084-0","article-title":"New inhibitors of prion replication that target the amyloid precursor","volume":"90","author":"Charveriat","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1128\/JVI.79.12.7785-7791.2005","article-title":"Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets","volume":"79","author":"Bertsch","year":"2005","journal-title":"J. Virol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/9\/1113\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:48:12Z","timestamp":1760111292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/9\/1113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":46,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["biom14091113"],"URL":"https:\/\/doi.org\/10.3390\/biom14091113","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]}}}